Dymista, a nasal spray used for allergic rhinitis, is not expected to have a generic version available in 2026 [1]. The patent for Dymista is set to expire in 2029 [2].
When will generic Dymista be available?
Generic versions of Dymista are anticipated to become available after the patent expires in 2029 [2]. Availability of generics can be influenced by various factors, including patent challenges and the regulatory approval process for generic manufacturers [1].
What is Dymista used for?
Dymista is prescribed to treat the symptoms of allergic rhinitis, commonly known as hay fever. It contains a combination of fluticasone propionate, an anti-inflammatory corticosteroid, and azelastine hydrochloride, an antihistamine [1]. This dual action helps to reduce inflammation and block the effects of histamine, thereby alleviating symptoms such as sneezing, itching, runny nose, and nasal congestion [1].
How does Dymista work?
Dymista's efficacy stems from its two active ingredients. Fluticasone propionate works by reducing inflammation in the nasal passages. Azelastine hydrochloride acts as an H1 antihistamine, preventing histamine from binding to receptors and causing allergic symptoms [1]. The combination targets multiple inflammatory pathways involved in allergic rhinitis.
What companies are involved with Dymista?
Dymista was developed by Meda Pharmaceuticals, which was later acquired by Mylan. Mylan then merged with Upjohn, a subsidiary of Pfizer, to form Viatris in 2020 [1][3]. Therefore, Viatris is the current manufacturer and marketer of Dymista.
What are the risks or side effects of Dymista?
Common side effects associated with Dymista include altered taste, nasal irritation, nosebleeds, and drowsiness [1]. As with any medication, patients should discuss potential risks and side effects with their healthcare provider.
What are the alternatives to Dymista?
For allergic rhinitis, alternative treatments include other nasal corticosteroid sprays, oral antihistamines, decongestants, and nasal antihistamine sprays [1]. The choice of treatment depends on the individual's symptoms, severity, and medical history.
What is the patent status of Dymista?
The primary patent for Dymista is scheduled to expire in 2029 [2]. DrugPatentWatch.com tracks patent information for various pharmaceuticals [1].
Sources:
[1] DrugPatentWatch.com
[2] https://www.drugpatentwatch.com/drug/dymista
[3] https://www.viatris.com/en/About-Viatris/Our-Company